Wesuggest that the termsubcli nica l cochlear hydrops be used to describe patients presenting with aural fullness, stuffiness, or ear pressure when all other diagnoses have beenexcluded. We reviewed the charts of20 patients who had presented with a chief complaint of aural fullness, stuffiness, or pressure and who underwent perfusion of theinner earfor 1 month with dexamethasone 4 or10mg/ ml. Thesymptoms improved in 13 (68.4%) of 19 patients aftertreatment. None of thesepatientsreported a worsening of symptoms, and no patient had worse hearingafter perfusion. Complications were infrequent, and patients tolerated the treatment well. Perfusion of the inner ear appears to be a safe procedure with little risk.
the im mune system, most commonly usin g systemic glucocorticoids or, m ore recen tly, intratympan ic stero ids.i" While treatment protocols remain var iable, th e use of intratympa nic steroids has gained favor among physic ians.
Diagnosing pa tients with cochlear hydro ps invo lves a thorough history an d physical examination along with d iagnostic testing, incl uding audiometry, electrocochleography, and brainstem responses, Patients presenting earl y in their course of cochlear hyd rops may not yet complain of hearing loss, but instead present with the chiefcomplaint ofaural fulln ess, stuffiness, or pressure. The neurotologic examination often does no t reveal the source of the patient's discomfort. To ru le out eustachian tube problems, the physic ian can have the patient perform the Valsalva m aneuver under direct visualization of the tym pani c membrane. If the patient is able to "pop" his or her ear, then eustachian tube probl ems are less likely. A thorough head and neck evalua tion is important to ru le out other sources of aural fullness, suc h as temporoman d ibular dysfuncti on , su pe rio r canal dehiscence, barotrau m a, and pa tulo us eustachia n tube. Once these conditions have been excluded, the physician is left wit h the dia gnostic cons ideration of cochlear hydrops.
Patients with cochlear hydrops will typ ically have a low-frequency sensory hearing loss. However, because of fluctuations in hearing, many patients will have norma l hea rin g upon presentation. Furthermore, patients ma y pre sent with aural fullnes s, stuffiness, or pressure as a clin ical precursor to coch lear hyd ro ps or Meniere disease. Subclinical cochlear hydrops has been the diagnosis given to patients with aural fullness, stuffiness, or pres sure with or without a sensory hearing loss once other etio logies have been ruled out.
As wit h cochlear hydrops, tre atment for subclinica l coch lear hyd rops is usually m edical. Patients are often prescribed d iureti cs, vasodilators (betah istine), and diet modificatio n (reduc tion in salt intake) . Another op tion for the acute present ation is a course of oral
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ana lysis, as hea ring loss was not their chief com plaint. None of th e patients ha d an air-bo ne gap.
Each chart was reviewe d for subjective changes in symptoms and/or complications, as well as objective information derived from pre-and postoperative audiometryand electrocochleography.Minim um follow-up therapy was 1 m on th post-procedure.
Perfusion regimen. The dexam ethasone perfusion in this study consisted of insertion of th e Silverstein MicroWick (figure) into th e tympanic m em bran e after th e patient was given 10 m g of diazepam. Th e ear canal was anesthetized wit h 2% lidocain e buffered with sodium bicarbonate (9 to 1), sim ilar to th e regim en used for m iddle ear surgery. A laser tympano stomy, or myr ingo to my, was performed over th e ro und window (RW ) area, after which a 30°, 1.7-mm endos cope was introduced to bett er visualize the RW niche. Any obs tructing m em branes were removed fro m th e RW area to allow for direct perfusion of the cochlea via the RW. A specia l 1.4-mm-diameter ven tilatio n tube was inserted into the tympanic membrane over the RW for perfusion of the inner ear. The MicroWick was inserted through the ventilation tube into the RW niche, and 0.2 mldexamethasone (4 or 10 mg/ml) was injected into the middle ear.
After the procedure, pat ients were instru cted to ins till 3 drops of dexam eth asone (either 4 or 10 mg/m l; mad e in a compounding pharm acy) three times a day and to use an antibioti c ear d rop at night to prevent infection. The perfusion tr eat m ent was con tinued for 4 weeks.
Evaluation. Audiometry and electro cochleography were per for m ed pr eop eratively and at 2, 4, and 8 weeks
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steroids : prednisone 60 mg da ily for 2 weeks followed by a tapered dose. However, system ic steroids carry certain risks and side effects of whi ch th e public is aware and th erefore rema ins cautious abo ut th eir use. System ic steroids are relatively contra in dicated Microwick in patients with diabetes, gastric ulcers, or glaucoma. Furthermor e, we reco gn ize th at use of a topical agent willdeliver a higher concentratio n of th e m edication to the cochlea.":" Our patients Fi gure. Illustrationshowsproperplacementof the Silverst ein Micro Wick. who were expe rienci ng acute sympto ms were offered the additional optio n of undergoing m iddle ear perfusion with dexam ethason e delivered via th e Silverstein MicroWick system .
The purpose of this article is to report th e results of trea ting patients who have wha t is believed to be a new diagnosis of subclinical coch lear hyd rops. Herein we present a ser ies of pat ients with th is diagnosis who have been treated with perfusion of the inner ear using th e MicroWick and dexam eth ason e dro ps for 1 mo nth. Clinical respo nse to th erapy and audiolcgic results will be reviewed.
Patients and methods
Between Jan 1, 2004, and Apr il 1, 2007, th e charts for all our patients who underwent perfusion of th e inner ear with dexamethaso ne were reviewe d. O nly th ose patients who und erwent the procedure for the chief comp laint of aural fullness, stuffiness , or press ure were inclu ded in this study; pati ents m ight or mig ht not have had a concurrent hearing loss in the problematic ear.
A total of 20 patients were identified who had undergone placement of the Silverstein MicroWick wit h dexamethasone (4 mg/ml [n =15] or 10 mg/ml [n =5]) perfusion for 4 weeks between 2004 and 2007. During the stu dy period, the protocol was changed fro m the 4 mg/ ml concentration to the 10 mg/m l concentration of dexam eth atson e in the hope of achievi ng a better clinical respo nse .
Of these 20 patients, 12 were fema les and 8 were m ales, with an average age of 59 years . The presenc e of a sensorine ural hearing loss did not pr eclude th e patient from undergoing th e proce dure or being included in th e
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Discussion
The clinical entity of coch lear hydrops has been well established. Many practitioners use cor ticosteroids in their treatment algorithm for these patients. Recently the use of transtympanic corticosteroid perfusion has found favor amo ng manyotologists. Once introduced to the RW, corticosteroids readily diffuse across th e mem-the electrocochleography scores were worse after treatment. Therefore, electrocochloeographycannot be used to indicate treatment success. Of the 19 pat ients for whom data were available, 2 (10.5%) receiving the 10 mg/m l conce ntration of dexamethasone experienced a persistent perforation.These perforations were easily repaire d wit ho ut complication using a fat graft myringoplasty. No other complications were observed in this set of patients. It appears th at the 10mg/ml dose resulted in a greater number ofpersistent perforations tha t needed repairing. Now we use 4 mg/ ml routinely.
After removing the MicroWick, we now rou tinely anesthetize the perforation with Gelfoam impregnated with lidocaine gel 2%, freshen the edge with a pick, and place a cigarette-paper patch over the perforation. This procedure has essentially eliminated persistent perforations. 
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Results
All 20 patients underwent the dexamethaso ne infusio n procedure with the primary objective of improvement in their aural fullness, pai n, or pressure. One patient was lost to follow-up evaluation .Fifteen ofthe patients underwent perfusion with dexamethasone 4 mg/ml, while 5 patients underwent perfusion with 10 mg/ml.
The chief complaint of aural fullness, stuffiness, or pressure was improved with the use of PTA =pure-toile audiometry; WDS =word-discrimination score the Micro Wick and dexamethasone perfusion in 13 (68.4%) of 19 patients; No improvement was observed in the remaining 6 (31.6%) patients. None of the patients repo rted a worsening of symptoms.
Audiologic data are presented in table 1. The mea n pure-tone average was 36 dB (SD =21) before th erapy and remained th e same after therapy, revealing no significant overall change in hearin g. However, S patients did exper ience a significant change in hearing: Two patien ts experienced a hearing loss (13 dB maximum), and 3 patien ts experienced an improvement (18 dB maximum) . The mean word-discrimina tion score was 82% (SD =27) before therapy, and 84% (SD =26) after therapy, with a mean improvement of 2%. Analysis of the pre-and post-treatment word-discrimination levels revealed that on ly 2 patients experienced a significant change. One patient's pre-and post-treatment puretone averages were 41 and 48 dB, respectively, for a loss of 7 dB. The other patient's pre-and post-treatment pure-tone averages were 66 and 51 dB, respecti vely, for a gain of 15 dB. Data from electrocochleography were available for 11 patients (table 2) . The summating potential/actio n potential rat io was calculated and considered to be abnorma l or elevated if it was 0.5 or greater. The ratio was elevated prior to therapy in 5 patients. An improvement in this ratio was noted in all 5 of these patients after therapy was administered. In 4 patien ts after the procedure. Pure -tone averages were calculated using the results at 0.5, 1, 2, and 4 kHz . Speech discrimination was also tested. A significant change in hearing was defined as a pure-tone threshold shift > 10 dB or a change in the speech discrimination score > 15%. Patien ts' symptoms were also evaluated subjectively at each visit and were graded as improved, the same, or worse. Fur thermore, any complication such as a persiste nt per fora tio n or infection was documented and included in th e ana lysis. In a fouryear study sponsored by the NIH involving children diagnosed with hearing loss from persistent Otitis Media with Effusion (OME), a few weeks of home treatment with the EarPopper restored hearing to normal in 85% of patients in the experimental group compared to 25% in the control group, without antibiotics or vent tubes.!l] brane into the perilymph. While the exact mechanism of action within the inner ear remains elusive, animal models have given us a good idea as to some of the effects ofthese medications. Corticosteroids suppress any immune-mediated inflammatory response. The y have also been shown to increase cochlear blood flow,u .rz as well as improving cochlear homeostasis. While all of these may be important, we still do not know how steroids provide symptom relief for patients with cochlear hydrops.
CLINICAL RESULTS
There are other benefits to transtympanic delivery of corticosteroids. This technique avoids the side effects associated with the use of systemic administration. Inner ear profusion, when compared with ora l administration, also allows for a higher concentration of the medication within the cochlea. Furthermore, with the use of the Silverstein Microwick, patients can perform a continuous perfusion of the inner ear, which may offer a therapeutic benefit over single injections.
The use of transtympanic dexamethasone has been widely reported, yet treatment protocols rem ain variable, as do clinical responses. Despite this uncertainty, the use remains widespread and gives patients an additional treatment option should medical therapy fail. Given the use of inner ear perfusion with dexamethasone to treat hearing loss for patients with cochlear hydrops, we sought to investigate its use for patients who present with the chief complaint of aural fullness, stuffiness, or pressure, all of which are common complaints to the otologist.
We identified a subset of patients with cochlear hydrops whom we define as having subclinical cochlear hydrops.These patients present with the chiefcomplaint of aural fullness , stuffiness, or pressure, with or without an associated mild hearing loss.
Other sources of aural discomfort, whether directly related to the ear or referred from other sources, are first excluded by history and physical examination and by ancillary testing. Important conditions to consider include eustachian tube dysfunction (obstructed or patulous), temporomandibular joint dysfunction, and superior semicircular canal dehiscence .While audiologic testing may reveal a sensory hearing loss, particularly in the low frequencies, which may support a diagnosis of hydrops, we did not preclude these patients from the study as their chief com plaint was aural discomfort, not hearing loss.
Treatment for subclinical cochlear hydrops parallels that of cochlear hydrops-mainly diuretics, diet modification, betahistine, and corticosteroids as warranted. We have begun treatment for patients with subclinical cochlear hydrops using the Silverstein Micro Wick and topical dexamethasone 4 or 10 mg/ml given for 1 month. This treatment permits perfusion of the inner ear, allowing a higher concentration of the steroid to circulate within the cochlea. Our rationale for using this therapy stems from the fact that dexamethasone perfusion carries a minimal risk to hearing while giving patients hope that a surgical intervention will provide them with symptom relief.
The change in the concentration ofdexamethasone in our patients reflects a change in protocol in which the concentration was at first increased from 4 mg/ml to 10 mg/ml in an effor t to achieve a bet ter clinical response. Data are insufficien t to confirm this hypothesis, as only 5 pat ients were perfused with the higher concentration; there are fewer chronic perforations in patients receiving the 4 mg/ml concentration, and the results are not better with the higher dose. Therefore, we now use 4 mg/ml routinely.
Audiologic data for patients treated for subclinical cochlear hydrops with transtympanic administration of dexamethasone reveal that hearing is not adversely affected by this treatment.
This article suggests a new clinical diagnosis (subclinical cochlear hydrops) for patients with aural fullness, stuffiness, or pressure when other diagnoses have been excluded. These patients are felt to have an early form of Meniere disease in which their hearing may not yet be affected. We have offered these patients a surgica l alternative with dexamethasone perfusion of the inner ear. We have seen a positive response in more than 68% of our patients, giving support to the theorythatthis may DEXAMETHASO NE INN ER EAR PERFUSIO N FO R SU BC LINICA L ENDOLYMPHATIC HYDRO PS be an immune-mediated condition. We recognize the lack oflong-term follow-up, as well as some of the other shortcomings ofth is study, yet we want to int roduce this th erapy as a new option for patients presenting with a complaint th at has historically been frus tra ting for th e physician to treat.
As of Decemb er 2008, many mo re patients have been treated, and the result s appear to be sustained in m ost patients. A longe r follow-up report is in progress.
